Morphine, a μ-opioid receptor (MOR) agonist, promoted the growth of NSCLC H460 cells both in vitro and in vivo; a higher morphine dosage shortens the survival time of patients with lung cancer [64]. Here, OPRM1 is linked to non-small cell lung carcinoma.